Please select the option that best describes you:
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
Answer from: at Academic Institution
The interim analysis of the AMPLIFY trial, published in the New England Journal of Medicine, presents strong evidence that could influence clinical practice for treatment-naïve chronic lymphocytic leukemia (CLL) patients without del(17p) or TP53 mutations. The AMPLIFY trial is the first phase 3...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Yes, these data have already changed my practice. For many patients, an all-oral fixed-duration doublet is preferable to venetoclax/obinutuzumab. From the AMPLIFY trial, I am comfortable giving acalabrutinib/venetoclax to patients with IGHV-mutated CLL. For those with unmutated IGHV who desire fixed...